Pure Biologics SA
Company Profile
Business description
Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.
Contact
ul. Dunska 11
Wroclaw54-427
POLT: +48 570002829
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
6
Stocks News & Analysis
stocks
Jet fuel price spike weighing on Australian airline profits
stocks
US utilities stocks keep rallying as investors bet on power demand growth
stocks
What did Morningstar subscribers buy and sell during March?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,190.90 | 19.30 | -0.21% |
| CAC 40 | 8,327.86 | 91.88 | 1.12% |
| DAX 40 | 24,044.22 | 301.78 | 1.27% |
| Dow JONES (US) | 48,535.99 | 317.74 | 0.66% |
| FTSE 100 | 10,609.06 | 26.10 | 0.25% |
| HKSE | 26,180.37 | 308.05 | 1.19% |
| NASDAQ | 23,639.08 | 455.35 | 1.96% |
| Nikkei 225 | 58,184.34 | 306.95 | 0.53% |
| NZX 50 Index | 13,066.62 | 49.36 | 0.38% |
| S&P 500 | 6,967.38 | 81.14 | 1.18% |
| S&P/ASX 200 | 8,987.90 | 23.50 | -0.26% |
| SSE Composite Index | 4,043.06 | 16.43 | 0.41% |